In recent years, Proton Pump Inhibitors (PPI) have been linked to serious health problems and all-cause mortality, suggesting that the acid reflux medication may do more harm than good. Studies show that PPIs cause damage to major organs and also lead to a higher risk of developing type 2 diabetes.
One study even argues that PPI usage increases mortality in COVID-19 patients. After testing nearly 300 hospitalized COVID-19 patients in Brooklyn, NY, researchers discovered that mortality was 2.3 times higher among PPI users. The authors of the study write that “severe acute respiratory syndrome coronavirus-2 may escape the inactivation by gastric acid because of hypochlorhydria caused by proton pump inhibitors,” predisposing the patients to severe cases of COVID-19 regardless of existing cardiovascular comorbidities.
Proton Pump Inhibitors and Skin Reactions
Additionally, PPI usage can lead to the development of life-threatening skin reactions. The Journal of Cosmetic Dermatology published data that revealed that the acid reflux medication increases the risk for skin issues, such as contact hypersensitivity and a form of lupus skin disease. More severe complications include Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
Finally, regular PPI users are often less physically active. They more frequently struggle with high blood pressure and high cholesterol. Studies published in Physician’s Weekly also note that usage may result in weight gain, metabolic syndrome, and chronic liver disease. Over-usage is linked to bone fractures, kidney disease, and dementia.
For more information about health complications associated with Proton Pump Inhibitors, contact us today.
Additional Reading:
Tracy Everhart
Tracy Everhart is the Editor for Drug Law Journal. A highly-trained and certified medical professional, Tracy is also an accomplished medical writer. After spending years on the front lines of the medical profession, Tracy now devotes her expertise and skills to researching and reporting on new drugs and devices that enter the market, as well as their side-effects and the real-life stories involved. Prior to joining Drug Law Journal, Tracy wrote for benchmark online healthcare resources focused on families and, in particular, women’s health issues. Tracy holds post-graduate degrees from both the American College of Healthcare Sciences and the Yale School of Nursing. She is also a graduate of both Hampshire College, where she studied microbiology and the University of South Carolina school of nursing.
